{"nctId":"NCT01056341","briefTitle":"Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy","startDateStruct":{"date":"2010-01"},"conditions":["Infantile Hemangioma"],"count":512,"armGroups":[{"label":"Propranolol oral solution","type":"EXPERIMENTAL","interventionNames":["Drug: Propranolol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Propranolol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Proliferating IH (target hemangioma) requiring systemic therapy anywhere on the body except on the diaper area with largest diameter of at least 1.5 cm\n\nExclusion Criteria:\n\n\\- The patient presents with one or more of the following medical conditions: Congenital hemangioma; Kasabach-Merritt syndrome; bronchial asthma; bronchospasm; hypoglycaemia (\\< 40 mg/dl or at risk); untreated phaeochromocytoma; hypotension (\\< 50/30 mmHg); second or third degree heart block; cardiogenic shock; metabolic acidosis; bradycardia (\\< 80 bpm); severe peripheral arterial circulatory disturbances; Raynaud's phenomenon; sick sinus syndrome; uncontrolled heart failure or Prinzmetal's angina; documented PHACES syndrome with central nervous system involvement\n\n* The patient has previously been treated for IH, including any surgical and/or medical procedures (e.g. laser therapy)\n* The patient is known to have a hypersensitivity to propranolol and/or any other beta-blockers\n* One or more of the following types of IH are present:\n\n  * Life-threatening IH\n  * Function-threatening IH (e.g. those causing impairment of vision, respiratory compromise caused by airway lesions, etc.)\n  * Ulcerated IH (whatever the localisation) with pain and lack of response to simple wound care measures\n* The patient was born prematurely and has not yet reached his/her term equivalent age (e.g. an infant born 2 months prematurely cannot be included before the age of 2 months)\n* LVEF (left ventricular systolic function) â‰¤40% and/or cardiomyopathy and/or hereditary arrhythmia disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Days","maximumAge":"150 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"9.8","spread":null},{"groupId":"OG002","value":"37.5","spread":null},{"groupId":"OG003","value":"7.7","spread":null},{"groupId":"OG004","value":"62.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Primary Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at W24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of W24 Photographs.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Success/Failure Based on the Investigator Qualitative Assessment of Complete Resolution at W48.","description":"Time to first sustained improvement based on centralized qualitative assessments of paired patient-visits","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":55},"commonTop":["Nasopharyngitis","Pyrexia","Teething","Upper respiratory tract infection","Bronchitis"]}}}